VAUGHAN, Ontario / Jul 11, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter 2023 financial results on Wednesday, Aug. 2, 2023. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.
Conference Call Details
Date: | Wednesday, Aug. 2, 2023 |
Time: | 8 a.m. ET |
Webcast: | |
Participant Event Dial-in: | +1 (888) 506-0062 (North America) +1 (973) 528-0011 (International) |
Participant Access Code: | 360419 |
Replay Dial-in: | +1 (877) 481-4010 (North America) +1 (919) 882-2331 (International) |
Replay Passcode: | 47446 (replay available until Aug. 16, 2023) |
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.
© 2023 Bausch + Lomb.
| Last Trade: | US$18.08 |
| Daily Change: | 0.18 1.01 |
| Daily Volume: | 341,874 |
| Market Cap: | US$6.370B |
December 11, 2024 October 30, 2024 October 14, 2024 July 31, 2024 June 17, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
